Bristol Myers Squibb and Eli Lilly posted fiscal 2025 results that confirm the market’s split verdict: one a deep-value dividend stock stabilizing after a loss year, the other a growth juggernaut printing 32 percent margins on weight-loss demand. The pair trade in the same sector but occupy different universes of risk and return, leaving investors to decide whether they prefer a 15 percent net margin backed by $12.8 billion of free cash flow or a 45 percent revenue surge funded by capacity build-out.
The numbers tell two stories
Bristol Myers revenue slipped 0.2 percent to $48.2 billion, essentially flat, while net income climbed to $7.1 billion from a prior-year loss. The turnaround yields a 15 percent net margin, respectable, but the top line shows no pulse. Eli Lilly, by contrast, grew revenue 45 percent to $65.2 billion and booked $21 billion of net income. The 32 percent margin reflects pricing power on Mounjaro and Zepbound that Bristol Myers’ legacy oncology franchise no longer commands.
Balance sheets reflect different bets
Bristol Myers carries a debt-to-equity ratio of 2.6 times, a level that signals reliance on borrowing to fund acquisitions and dividends. Its current ratio of 1.3 times offers a thinner liquidity cushion. Eli Lilly’s debt-to-equity sits at 1.6 times with a 1.6 times current ratio, a structure built to absorb the $9 billion of free cash flow it plows back into manufacturing expansion. The contrast is stark: one company returns cash, the other reinvests it at scale.
Patent cliff looms for one
The Inflation Reduction Act price-negotiation framework targets Bristol Myers’ top sellers, Eliquis and Opdivo, while patent expirations threaten to open the door to generics. The company’s recent exit from a Breyanzi manufacturing partnership underscores the difficulty of scaling complex cell therapies as exclusivity windows narrow. Eli Lilly faces its own patent calendar, but the metabolic franchise is still in its early commercial innings, giving it more runway before the cliff arrives.
What to watch next
Bristol Myers must prove its pipeline can replace eroding blockbusters without further leverage. Eli Lilly must demonstrate that manufacturing scale keeps pace with demand and that margins hold once competitors enter the GLP-1 market. The valuation gap between a high-yield value trap and a high-multiple growth story will narrow only when one side breaks its current trajectory.